Intellectual property rights over artificial genomes

Introduction

Artificial genomes are laboratory-designed or synthetically constructed genetic sequences developed through biotechnology and synthetic biology. They may involve the modification, reconstruction or creation of DNA sequences for applications in medicine, agriculture, industrial biotechnology and scientific research.

Artificial genomes can be used to develop synthetic microorganisms, produce medicines, improve agricultural characteristics and manufacture biological products. Their development raises important intellectual property rights (IPR) questions concerning patent ownership, genetic information, biological materials, research data and commercial exploitation.

In India, intellectual property protection for artificial genomes is primarily governed by the Patents Act, 1970, the Copyright Act, 1957, the Biological Diversity Act, 2002 and applicable biotechnology regulations.

Patentability of artificial genomes

Patents are the principal intellectual property mechanism for protecting qualifying artificial genome-related inventions. A researcher or biotechnology company may seek patent protection for a synthetically constructed DNA sequence, genetically engineered microorganism, novel genetic construct or innovative biological manufacturing process.

Under Section 2(1)(j) of the Patents Act, 1970, an invention must satisfy three essential conditions:

Novelty: The invention must not already be publicly known.

Inventive step: It must involve a technical advance or economic significance that is not obvious to a person skilled in the relevant field.

Industrial applicability: It must be capable of being made or used in industry.

However, artificial genomes face important statutory restrictions.

Section 3(c) excludes the mere discovery of a living thing or non-living substance occurring in nature. Therefore, naturally occurring genetic sequences cannot automatically receive patent protection merely because researchers identify them.

Section 3(j) excludes plants and animals, in whole or in part, other than microorganisms, including seeds, varieties and species, as well as essentially biological processes for their production or propagation.

Consequently, a genetically engineered microorganism may potentially qualify for patent protection if it satisfies the statutory requirements. However, the patentability of an artificial genome must be assessed according to its specific technical features and claims.

Ownership of synthetic genetic material

Ownership of artificial genomes creates complicated legal questions because their development may involve several contributors, including scientists, universities, research institutions and biotechnology companies.

For example, a university researcher may design a genetic construct, while a commercial laboratory develops the technology for producing it. Disputes may arise concerning inventorship, ownership and commercial licensing.

Under Section 6 of the Patents Act, 1970, an application for a patent may be made by the true and first inventor, an assignee or the legal representative of a deceased person entitled to apply.

Section 7 deals with the filing of patent applications, while Section 10 establishes requirements concerning the specification and disclosure of inventions.

Employment agreements, research collaboration contracts and technology-transfer agreements are therefore important for determining ownership of artificial genome inventions.

Protection of genetic information and digital genome sequences

Artificial genome research frequently involves digital DNA sequence information, genetic databases and computer-generated biological models.

The Copyright Act, 1957 may protect original scientific software, research publications, diagrams and qualifying database arrangements. However, copyright does not automatically protect genetic information, scientific facts or biological sequences themselves.

Trade secret protection may also apply to confidential genome-design methods, proprietary research databases, manufacturing techniques and unpublished experimental information.

The protection of genetic information must also consider privacy and ethical requirements where identifiable human genetic data is involved. India's Digital Personal Data Protection Act, 2023 may apply where such information constitutes personal data and the relevant provisions are in force.

Biodiversity and access-related regulations

Artificial genomes may be developed using genetic materials obtained from plants, animals, microorganisms and other biological resources.

The Biological Diversity Act, 2002 provides a framework for regulating access to biological resources occurring in India and associated traditional knowledge. Its requirements depend on the identity of the applicant, the nature of the research and the intended utilisation.

The Convention on Biological Diversity, 1992 and the Nagoya Protocol, 2010 also provide international principles concerning access to genetic resources and fair and equitable benefit-sharing.

A synthetically reconstructed genome does not automatically eliminate legal questions concerning the original biological resources used in its development.

Important judicial decisions

There are limited Indian judicial decisions directly addressing intellectual property rights over artificial genomes. However, the following judgments establish relevant principles by analogy.

1. Diamond v. Chakrabarty, 447 U.S. 303 (1980)

The United States Supreme Court held that a genetically engineered microorganism capable of breaking down multiple components of crude oil could qualify as patentable subject matter under American patent law.

The judgment became an important precedent in biotechnology patent law. It demonstrated that a human-made microorganism with characteristics significantly different from naturally occurring organisms could receive patent protection under the applicable American legislation.

Its reasoning is influential internationally, although it does not determine patentability under Indian law.

2. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

The United States Supreme Court held that naturally occurring DNA segments are not patentable merely because they have been isolated. However, synthetically created complementary DNA (cDNA) may be patentable in circumstances where it is not identical to naturally occurring DNA.

This judgment is particularly relevant to artificial genomes because it distinguishes naturally occurring genetic material from certain human-created genetic constructs.

3. Novartis AG v. Union of India (2013) 6 SCC 1

The Indian Supreme Court interpreted Section 3(d) of the Patents Act and emphasised the statutory requirements for patenting modified forms of known substances.

Although the case concerned pharmaceutical technology rather than artificial genomes, its reasoning is relevant to applications involving modified genetic materials and biological compositions.

4. Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979) 2 SCC 511

The Supreme Court explained the importance of novelty and inventive step in patent law.

The decision is relevant because artificial genome inventions must demonstrate genuine technical advancement rather than merely combining known genetic elements through obvious techniques.

5. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) 3 SCC 381

The Supreme Court considered patent-related disputes involving genetically modified seeds and biological technology. The litigation demonstrates the difficulties of applying patent law to inventions involving living organisms and genetic modification.

Its principles may assist in understanding disputes concerning genetically engineered microorganisms and synthetic biological systems, although it does not directly determine artificial genome ownership.

Challenges in intellectual property protection

Artificial genome technology creates several important legal challenges:

Natural versus synthetic sequences: Distinguishing patentable human-created inventions from discoveries of naturally occurring genetic material.

Inventorship disputes: Determining contributions when multiple researchers and automated design systems participate in development.

Access to genetic resources: Ensuring compliance with biodiversity and benefit-sharing requirements.

Research accessibility: Balancing commercial patent rights with scientific research and public health interests.

International protection: Different countries may apply different standards to biological inventions and genetic sequences.

Conclusion

Intellectual property rights over artificial genomes represent an important developing area of biotechnology law. Patent protection may be available for genuinely novel and inventive synthetic genetic constructs, genetically engineered microorganisms and associated technological processes. However, naturally occurring genetic material and certain biological subject matter face statutory restrictions. Decisions such as Diamond v. Chakrabarty, Myriad Genetics and Novartis AG v. Union of India provide important principles for distinguishing discoveries from patentable inventions. A balanced legal framework must protect scientific innovation while respecting biodiversity, research ethics and equitable access to genetic resources.